We have previously shown that the synthetic tetraacyl precursor Ia (compound 406, or lipid IVa) was not able to induce the production of tumor necrosis factor, interleukin-1, and interleukin-6 in human monocytes but strongly antagonized lipopolysaccharide (LPS)-induced formation of these monokines. This inhibition was detectable at the level of mRNA production. To achieve a better understanding of molecular basis of this inhibition, we investigated whether lipid A precursor Ia (LA-14-PP), Escherichia coli-type lipid A (LA-15-PP), Chromobacterium violaceum-type lipid A (LA-22-PP), and synthetic lipid A partial structures and analogs (LA-23-PP, LA-24-PP, and PE-4) were able to influence the binding of 125I-LPS to human monocytes and compared this inhibitory activity with the agonistic and antagonistic action in the induction of monokines in human monocytes. 12sI LPS (20 ng per well) was added to human monocytes in the presence or absence of unlabeled rough Re mutant-derived LPS (Re-LPS) or lipid A compounds, and specific LPS binding was determined after 7 h. This binding was found to be dependent on CD14 as shown by the use of an anti-CD14 monoclonal antibody. Compound LA-14-PP was found to inhibit the binding of '25I-LPS to the cells in a similar dose-response to that of unlabeled LPS. This shows that the inhibitory capacity on LPS binding does not correlate with the monokine-inducing capacity because Re-LPS is active in inducing tumor necrosis factor, interleukin-1, and interleukin-6, while LA-14-PP is not. The strong capacity of LA-14-PP to inhibit 125I-LPS binding, however, correlates with the strong inhibitory capacity of this compound on LPS-induced monokine production. Compounds LA-15-PP, LA-23-PP, and LA-24-PP were active in the inhibition of 1251-LPS binding but were 5-to 10-fold weaker than Re-LPS and LA-14-PP. Of all lipid A structures tested, compound LA-22-PP expressed the weakest inhibitory capacity on LPS binding. These compounds showed again that the activity of binding inhibition does not correlate with the monokine-inducing capacity. We assume that the inhibitory effects of lipid A partial structures on LPS-induced monokine production have their origin in a competitive inhibition between LPS and the lipid A partial structures for the same binding site on the cell membrane.
Lipopolysaccharide (LPS), also known as endotoxin, from the outer leaflet of the outer membrane of gram-negative bacteria is considered to be responsible for the induction of pathophysiological reactions of an infected host (25, 27) . It is known today that the pathophysiological effects of endotoxin are not due to a direct action of LPS but are elicited by various mediators including tumor necrosis factor (TNF), interleukin-1 (IL-1), and interleukin-6 (IL-6) and, furthermore, that monocytes or macrophages are the miajor source of these mediators.
LPS consists of a hydrophilic polysaccharide and a covalently linked hydrophobic lipid part, termed lipid A. Lipid A represents the endotoxic principle of LPS, i.e., the biological effects of LPS are reproduced by free lipid A (2, 8) . The successful chemical synthesis of lipid A and corresponding partial structures of LPS, such as Escherichia coli-type lipid A (compound 506, LA-15-PP) and precursor Ia (compound 406, LA-14-PP, or lipid IVa) has provided the experimental basis to investigate the bioactive regions of LPS with regard to structure-activity relationships (2, 8, 12, 19, 25) . A structure-dependent hierarchy of LPS and LPS partial structures * Corresponding author.
with respect to their IL-l-, IL-6-, and TNF-inducing capacity was demonstrated, showing that the hexaacyl type lipid A LA-15-PP is able to induce monokine production by human monocytes, while the tetraacyl compound LA-14-PP exhibited no inducing capacity (4, 22) . The synthetic LA-14-PP became of particular interest since our studies as well as those of others showed that LA-14-PP was able to block LPS-induced monokine production in human monocytes in a specific manner (5, 16, 21, 36, 37) . Therefore, this compound may be able to prevent the fatal endotoxin-induced reactions of an infected host. To achieve a better understanding of the molecular basis of this inhibition, we have investigated whether LA-14-PP and other synthetic lipid A partial struc- article. When comparing the inhibition of binding of I251-LPS with the inhibition of biological activity, we found that both LA-14-PP as well as its phosphonooxyethyl analog PE-4 are the best tested inhibitors of LPS binding to human monocytes as well as preventers of monokine production tested here. Taken together, our results provide strong evidence for the concept that inhibition of LPS-cell interaction by LA-14-PP and other lipid A partial structures is based on a competitive inhibition of a specific LPS-binding protein of the responder cell.
MATERIALS AND METHODS LPS, synthetic lipid A, precursor la, and lipid A analogs. LPS of Salmonella friedenau and Salmonella minnesota R595 core-defective deep rough Re mutant (Re-LPS) were prepared with the phenol-water method (38) and the phenolchloroform-petroleum ether method (9) , respectively, purified by repeated ultracentrifugation, and converted to the uniform sodium salt after electrodialysis as reported previously (7) . Such preparations contain less than 0.1% of protein and nucleic acid as determined by chemical analysis.
Synthetic hexaacyl E. coli-type lipid A, LA-15-PP (or compound 506), is composed of a bisphosphorylated glucosamine disaccharide with six acyl residues and structurally corresponds to free lipid A prepared from LPS of the E.
coli Re-mutant strain F515. It was synthesized as described previously (12) . Synthetic LA-22-PP is a hexaacylated lipid A but differs from LA-15-PP in the acylation pattern as indicated in Fig. 1 . Synthetic tetraacyl lipid A precursor Ia (compound 406 or LA-14-PP) represents a partial structure of LA-15-PP lacking dodecanoic and tetradecanoic acids. LA-14-PP was synthesized as described elsewhere (13) . Synthetic LA-23-PP and LA-24-PP are tetraacyl lipid A partial structures which differ from LA-14-PP in the pattern of acylation as indicated in Fig.  1 . Preparation PE-4 is a synthetic analog of LA-14-PP having an oxyethyl-linked (-O-CH2-CH2-) phosphoryl group in position 1 of the reducing glucosaminyl residue (GlcN I). This phosphonooxyethyl analog of LA-14-PP was synthesized as described previously (17, 18) .
All synthetic compounds were stored in aliquots at 1 mg/ml at 4°C. The chemical structures of the compounds are given in Fig. 1 .
Isolation of human PBMC and monocytes. Peripheral blood mononuclear cells (PBMC) from healthy donors were isolated by density gradient centrifugation (35) with FicollPaque (Pharmacia, Uppsala, Sweden). Monocytes were isolated from PBMC by elutriation in a J2-21 M/E Elutriator (Beckmann, Munchen, Germany) as described elsewhere (5 (1:6) . A standard preparation of IL-6 giving 150 IU/ml was used as a positive control. After incubation (37°C, 5% C02, 48 h), 10 pl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) (5 mg/ml in phosphatebuffered saline [PBS] , pH 7.4) was added to each well, and cells were further incubated for 3 h (37°C, 5% C02). The MTT reaction was stopped by adding 100 ,ul of acidified isopropanol (0.04 N HCI in isopropanol) per well, and MTT7 formazan was dissolved by vigorous mixing with a stirring machine. The A550 was measured with a microplate reader (MR 700, Dynatech). IL-6 activity in the samples was determined by using a standard of recombinant human IL-6 with a specific activity of 107 U/mg (from Genzyme Fine Chemicals, Boston, Mass.) and by comparing the dilutions giving 50% proliferation by probit analysis (10) . The results are given in units of IL-6 per milliliter.
Preparation of "2'I-LPS. Radiolabeled 1"I-LPS was prepared by the method described by Ulevitch (34) with some modifications. In brief, S. minnesota R595 LPS was coupled to p-OH methylbenzimidate by incubation in 50 mM borate buffer (pH 8.0) for 18 h at 37°C. p-OH methylbenzimidatecoupled LPS was radiolabeled with 1 mCi of Na 125I (Amersham Buchler, Braunschweig, Germany) per mg of LPS in a solid-phase reaction using IODO-BEADS (Pierce, Rockford, Ill.). One mole of methylbenzimidate was introduced per about 1,000 mol of Re-LPS (estimated molecular weight, 2,800). The radiolabeled LPS had a specific activity of 1.1 to 2.8 p,Ci/,ug (1 to 2 mol of 125I-LPS per 1,000 mol of LPS). The biological activity of LPS was not significantly altered by the radiolabeling procedure as measured by the induction of monokines in human PBMC. Retention of the biological activity indicates that the structure of R595 LPS was not substantially affected by the radiolabeling procedure, which could be expected if, for example, the ester linkages in the lipid A were influenced. However, since only 1 per 1,000 molecules was labeled, we cannot exclude that an actually labeled 1`I-LPS molecule has a different biological activity than an unlabeled LPS after the labeling procedure.
Binding assay for 125I-LPS. Binding of "'I-LPS was performed by a method described elsewhere (15) . In brief, monocytes (7 x 105) were incubated in 1 ml of RPMI 1640 medium plus 10% FCS in 24-well Costar tissue culture plates (Technomara, Fernwald, Germany) overnight at 37°C, in 5% CO2. After the plates were washed three times with PBS, 280
,ul of ice-cold Hanks' balanced salt solution with 5% FCS and 0.1% sodium azide was added to the adherent cells. The plates were put on ice, and 10 ,ul of unlabeled LPS, another unlabeled competitor, or anti-CD14 monoclonal antibody (clone MEM18; kindly provided by V. Bazil, Prague, Czechoslovakia) was added, followed by the addition of 10 pl of '"I-LPS (2 ,g/ml). After gentle shaking, the cells were incubated for 7 h on ice in a refrigerator. Binding was terminated by washing the cells two times with ice-cold Hanks' balanced salt solution containing 5% FCS and 0.1% sodium azide and two times with ice-cold PBS. The cells were lysed by the addition of 500 ,ul of 0.1 N NaOH, and the radioactivity of the solubilized cells was measured in a gamma counter. Specific binding was defined as the differences between radioactivity of samples incubated with excess (25-fold) unlabeled LPS (nonspecific binding) and the radioactivity measured in the absence of unlabeled ligand (total binding). LA-14-PP) or the synthetic analog PE4, it was found that they were not able to induce monokine production in human PBMC even at a concentration of 1,000 ng/ml (Fig. 3) . Inhibitory effects of LA-14-PP, LA-24-PP, and PE-4 on monokine production. Experiments were performed to investigate the inhibitory effects of noninducing synthetic tetraacyl compounds on monokine production. In the first experiments, the inhibitory effect of precusor Ia (LA-14-PP) on LPS-, LA-15-PP-, or LA-22-PP-induced monokine production was analyzed. Cells were first treated for 30 min with LA-14-PP (250 ng/ml) and then stimulated with different concentrations of LPS, LA-15-PP, or LA-22-PP. The results presented in Fig. 4 show that 250 ng of LA-14-PP per ml is able to block monokine production induced by LA-15-PP or LA-22-PP at every concentration tested (up to 100 ng/ml). In contrast, LPS-induced monokine production was abolished only up to a ratio of 1 ng of LPS per ml to 250 ng of LA-14-PP Fig. 2. per ml. At concentrations of 10 ng of LPS per ml or higher, only a partial inhibition by LA-14-PP was observed. In addition, the inhibitory capacities of compounds LA-24-PP and PE-4 were compared with that of LA-14-PP. Human PBMC were preincubated with LA-14-PP, LA-24-PP, or PE-4 at a concentration of 250 ng/ml, and after 30 min, the cells were stimulated with different amounts of LPS. A comparison of the effect of LA-24-PP with that of LA-14-PP reveals that, as expected (Fig. 4) , LA-14-PP abolished IL-1 release after stimulation of the cells with LPS at concentrations of up to 1.0 ng/ml (Fig. 5) . On the other hand, LA-24-PP was found to have a lower inhibitory activity, blocking only at an LPS concentration of 0.1 ng/ml (Fig. 5) . At higher LPS concentrations (10 or 100 ng/ml), LA-24-PP even enhanced IL-1 release. Compound PE-4 exhibited an inhibitory effect quite similar to that of compound LA-14-PP (Fig. 6) (Fig. 7A, C, and D) . Compound LA-22-PP expressed the lowest inhibitory activity of 125I-LPS binding to cells (Fig. 7B) . These data indicate that, at least with these special structures, there is only a partial correlation between the capacity of inducing monokine production in human PBMC by these compounds and the inhibition of binding of 15I-LPS.
To characterize the binding structure which reacts with '"I-LPS, the binding assay was performed in the presence of an anti-CD14 monoclonal antibody (clone MEM18 Human monocytes (7 x 105 per well) were incubated with '25I-LPS in the presence or absence of unlabeled LPS, lipid A, or related partial structures at different concentrations as indicated. After incubation for 7 h on ice, the cells were washed four times and lysed by the addition of NaOH, and the radioactivity was measured with a gamma counter. The results are expressed as percent inhibition of specific binding of 1"I-LPS to the cells. Each value represents the mean ± standard deviation of three independent wells. inactive in inducing IL-1, IL-6, and TNF release in human monocytes (4, 16, 22, 36) . In addition to LA-15-PP and LA-14-PP, we have now tested several other new synthetic lipid A partial structures and investigated the inhibition of binding of 1"I-LPS to gain better insight into the structureactivity relationship and the mechanism of action of these structures, respectively.
Compounds LA-15-PP and LA-22-PP do not differ in the number of acyl residues but show a different distribution pattern (Fig. 1) . Although this seems to be only a slight modification, our results show that LA-22-PP has a markedly lower monokine-inducing activity than LA-15-PP (Fig. 2) . The reduced biological activity might be caused by a reduced affinity to a receptor(s), since LA-15-PP has a much stronger inhibitory effect on the binding of '"I-LPS to monocytes than LA-22-PP does (Fig. 7) . Thus, asymmetrically acylated LA-15-PP is more active than symmetrically acylated LA-22-PP, indicating that a different distribution of lipid A fatty acids results in a marked alteration of the biological activity. As already described for LPS-induced monokine production (5, 16, 21, 33, 36, 37) , the biological activity of LA-15-PP as * Re-U'S o LA-14-PP v LA-1 5-PP well as LA-22-PP can be inhibited by precusor Ia (LA-14-PP) (Fig. 4) . The inhibitory activity of 250 ng of LA-14-PP per ml can be observed even in the presence of 100 ng of LA-15-PP or LA-22-PP per ml; this is in contrast to its inhibitory effect on LPS-induced monokine production, which can be totally blocked at a concentration as low as 1.0 ng of LPS per ml (Fig. 4) . This again reflects the lower affinity of LA-15-PP and LA-22-PP to its receptor(s) in comparison with that of LPS. The fact that compound LA-23-PP is able to induce monokines, although to a small extent, was not expected. Compound LA-23-PP represents, like LA-14-PP, a tetraacylated lipid A partial structure (Fig. 1) . In contrast to LA-14-PP, it contains four residues of nonhydroxylated decanoic acid (10:0) .
In addition to LA-23-PP, two other analogs of LA-14-PP, i.e., LA-24-PP and PE-4, were investigated regarding their activity. LA-24-PP carries 2 mol of nonhydroxylated decanoic acid in addition to two hydroxylated acyl residues resulted in a compound which was, like LA-14-PP, not active in inducing monokines in human monocytes (Fig. 3) . However, the inhibitory activity of LA-24-PP is much less pronounced than that of LA-14-PP on LPS-induced IL-1 production (Fig. 5) . This low inhibitory bioactivity is accompanied by a low capacity to inhibit the binding of 1"I-LPS (Fig. 7) . In this respect, compound LA-24-PP is comparable to LA-15-PP and LA-23-PP.
Compound PE-4 differs from LA-14-PP in containing an a-oxyethyl(-O-CH2-CH2-)-linked phosphoryl group in position 1 of the reducing glucosamine residue of lipid A. From the biological point of view, the a-glycosyl phosphate group has been found to be of special significance for the biological activity of lipid A or LPS, since its absence resulted in a dramatic reduction of biological activity (26, 28) . Our results indicate that the introduction of the oxyethyl linkage does not cause a considerable alteration in the activity of the compound. This was found not only with respect to the bioactivity but also when the inhibition of binding of 11I-LPS to monocytes was investigated. This finding is of special importance. This novel lipid A analog can be more easily synthesized and purified and is more stable than the regular synthetic compound LA-14-PP. Furthermore, such stable a-phosphonooxyethyl glycosides make synthetic strategies more flexible and extend the possibilities to create new compounds for laboratory and clinical application.
In conclusion, the data presented here and elsewhere (reviewed in reference 26) suggest that the biological activity of lipid A and lipid A partial structures depends on the phosphorylation and acylation pattern of the hexosamine A discrepancy between competition in a 125I-LPS binding assay and the induction of TNF and IL-6 by various lipid A partial structures has already been described in mouse macrophage-like J774.1 cells (15) . These experiments lead to the conclusion that the hexosamine backbone with its two phosphoryl groups is involved in the specific binding of lipid A to a receptor, whereas the number, type, and distribution of fatty acids are critical for the induction of cytokine production (15 (32) . Certainly, the physical state of these aggregates depends on experimental conditions, which differ in our bioassays and binding assays. Therefore, one simple explanation for the different outcomes of the biological assays and the binding assays may be the different conformations of the compounds under the different incubation conditions, resulting in a variation in binding affinity. This situation becomes more complex because LPS and lipid A will also interact with binding proteins that are present in a soluble form in the serum (3, 24, 31) , proteins which are known to be involved in the biological and binding activities of LPS. In view of the fact that induction of IL-1 and IL-6 was carried out in the absence of serum, while the binding experiments had to be done in the presence of serum because of experimental conditions, some control experiments were performed (data not given) that proved the effect of serum on IL-1 and IL-6 induction. We have found that also in the presence of serum, LA-15-PP but not LA-14-PP is able to induce monokine production and, furthermore, that LA-14-PP blocks LPSinduced monokine production. We, therefore, assume that the structure-activity requirements of LPS and lipid A are not affected by serum supplementation. On the other hand, several different binding structures for the binding of LPS to macrophages or monocytes have been described. CD14 is one of the LPS-binding proteins on the surface of monocytes which is involved in LPS-mediated induction of monokines (14, 29, 30, 39) . As shown in Table 1 , the binding of '"I-LPS can be totally blocked by a monoclonal antibody against CD14 (MEM18), and, furthermore, anti-CD14 is able to abrogate LPS-induced monokine production (data not given). This indicates the central role of this antigen during binding of LPS to human monocytes and during induction of monokine production. Nevertheless, although binding of 1"I-LPS is CD14 dependent, one may assume that the different structureactivity requirements for binding and induction of monokines may reflect different additional binding elements in both assays. However, our experiments performed in human monocytes provide no information towards a characterization of such a binding structure, which is also involved with CD14 in our bioassays and binding assays.
